TocilizumabV1, Hal, Checkpoint, indexHead, KwdEn.i

Index : Keywords

Les termes de plus forte occurence

11	tocilizumab
7	Tocilizumab
5	rheumatoid arthritis
3	human
3	Rheumatoid arthritis
3	Arthritis
2	uveitis
2	treatment
2	rapamycin
2	polymyalgia rheumatica
2	mycophenolate mofetil
2	interleukin-6
2	interferon
2	infliximab
2	inflammation
2	eular recommendations
2	corticosteroids
2	azathioprine
2	adalimumab
2	TOCILIZUMAB
2	Macrophage activation syndrome
2	Humans
2	Cytokines
2	Biologics
2	B cells
2	Anakinra
2	Adult
2	Adult-onset Still's disease
1	visual acuity/drug effect
1	uveitis/ drug therapy
1	tumor necrosis factor-alpha/antagonist & inhibitor
1	tumor necrosis factor-alfa inhibitors
1	treatment planning
1	treatment outcome
1	tomography
1	systemic glucocorticoid therapy
1	steroid
1	sarcoidosis
1	risk
1	retina/anatomy & histology/drug effect
1	remission
1	regulatory T cells
1	registry regate registry
1	receptor
1	prospective follow-up
1	photometry
1	perimetry
1	perforin
1	paradoxical reactions
1	optical coherence
1	nephropathy
1	natural killer cells
1	multimodal imaging
1	monoclonal
1	modifying antirheumatic drugs
1	methotrexate
1	management
1	macular edema
1	macular edema/drug therapy
1	laser flare photometry
1	interleukin
1	interleukin-6/antagonist & inhibitor
1	interleukin-6 receptor inhibition
1	interleukin-6 inhibitor
1	infusion-related reactions
1	inadequate response
1	immunosuppressive agent
1	immunosuppressive agent/ therapeutic use
1	il-6 receptor subunits
1	humanized/ therapeutic use
1	hidradenitis suppurativa
1	granzyme
1	female
1	factor-alpha inhibitors
1	electroretinography
1	drug indication
1	drug effect
1	diseases
1	disease-activity
1	dendritic cell
1	danish danbio registry
1	cytokines
1	cytokine
1	corticosteroid
1	controlled-trial
1	clinical-practice
1	clinical study
1	clinical evaluation
1	cerebrospinal fluid
1	central nervous system
1	cardiovascular risk
1	cardiovascular disease
1	cancer recurrence
1	canakinumab
1	biologics
1	biological therapy
1	biological product
1	biological agents
1	biological DMARDs
1	biologic agents
1	apolipoprotein
1	antibody
1	anti-TNF drug
1	anakinra
1	aged
1	adult
1	adult-onset Still\textquoterights disease
1	adrenal cortex hormones/therapeutic use
1	adipokine
1	Vasculitis
1	Uveal melanoma
1	Treatment
1	Treatment strategy
1	T-cell
1	Systemic Lupus Erythematosus
1	Still's Disease
1	Short Survey
1	Severity of Illness Index
1	Sarcopaenia
1	STAT3
1	Ruxolitinib
1	Rituximab
1	Risk Factors
1	Rheumatology
1	Rheumatoid
1	Rheumatoid Arthritis
1	Review
1	Relapsing polychondritis
1	Relapse
1	Registries
1	Quality Control
1	Prognosis
1	Probenecid
1	Polarization
1	Pharyngitis
1	Peptides
1	PHARMACOKINETICS
1	PD-1
1	PATHWAYS
1	Ovarian cancer
1	Nivolumab
1	NEUTROPENIA
1	Myelodysplastic syndrome
1	Multivariate Analysis
1	Mouse
1	Monoclonal
1	Middle Aged
1	Microenvironment
1	Methotrexate
1	Metastases
1	Metabolic change
1	Mesenchymal stromal cell
1	Male
1	Macrophage
1	Logistic Models
1	Legionella bozemanii
1	LEFLUNOMIDE
1	Juvenile Idiopathic Arthritis
1	JAK inhibition
1	Intravenous
1	Interleukin 6
1	Interleukin 10
1	Inoculation
1	Innate
1	Infusions
1	Inflammation
1	Immunosuppression
1	Immunity
1	Immune-related adverse events
1	Il-6
1	INFECTION
1	Hypertension
1	Hyperferritinemia
1	Humanized
1	Human Hepatocyte
1	Hepatic inflammation
1	Hemophagocytic lymphohistiocytosis
1	Giant-cell arteritis
1	Giant cell arteritis
1	Genetic Predisposition to Disease
1	GENETIC-POLYMORPHISM
1	Female
1	Extrapulmonary infections
1	Esophageal stenosis
1	Drug Transporter
1	Drug Eruptions
1	Disease Activity
1	Dermatomyositis
1	Denosumab
1	DRUG-INTERACTIONS
1	DMARDs (synthetic)
1	DMARDs (biologic)
1	Cyclic
1	Corticosteroids
1	Corticosteroid
1	Clinical trial
1	Chemoresistance
1	Checkpoint inhibitors
1	Cachexia
1	CELECOXIB
1	C-reactive protein
1	Biologics Key messages
1	Behcet disease
1	Autoinflammatory disorder
1	Autoimmune Diseases
1	Aortitis
1	Antirheumatic Agents
1	Antibodies
1	Anti-TNF agents
1	Anaphylaxis
1	Amyloid A amyloidosis
1	Aged
1	Adult-Onset
1	Adaptive Immunity
1	Acute hepatitis E
1	Abatacept
1	ARTHRITIS
1	ANTIRHEUMATIC AGENTS
1	ACTIVE METABOLITE
1	A77 1726
1	16S rRNA PCR
1	registries and rheumatoid arthritis (RA)
1	Trastuzumab
1	Quality control
1	Proteolysis
1	Proteolysis product separation
1	Pharmaceutical
1	Osmolar Concentration
1	Monoclonal
1	Monoclonal antibody
1	In-line digestion
1	Hydrogen-Ion Concentration
1	Humanized
1	Enzyme Assays
1	Enzymatic microreactor
1	Electrophoresis
1	Chemistry
1	Capillary
1	Capillary electrophoresis
1	Automation
1	Antibodies

Manipulations en shell (Unix/Dilib)

HfdCat /Users/jacquesducloy/Documents/WicriRoot/Wicri/Sante/explor/Tocilizumab.storage/TocilizumabV1/Data/Hal/Checkpoint/KwdEn.i.hfd| SxmlCut idx/l | grep ...

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

	Serveur d'exploration Tocilizumab - Checkpoint (Hal) Index « Mots-clés originaux en anglais » - tête de navigation
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Tocilizumab - Checkpoint (Hal)Index « Mots-clés originaux en anglais » - tête de navigation

Index : Keywords

Les termes de plus forte occurence

Manipulations en shell (Unix/Dilib)

Serveur d'exploration Tocilizumab - Checkpoint (Hal)

Index « Mots-clés originaux en anglais » - tête de navigation